Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype
Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype
Chonlatis Srichumpuang, Nuttarak Sasipong, Chatphatai Moonla, Itsaraet Gosriwatana et al.
Citations
9 citations
Journal
Haemophilia
Topics
Hemophilia Treatment and Research
Field-Weighted Citation Impact (FWCI)
4.09
article
Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype